Arcturus Therapeutics (ARCT) AI Stock Analysis

• Market Cap: $242.49M
• Dividend Yield: N/A
• Average Volume (3M): 829.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: -41.53%
• EPS Growth: -11.32%
• Country: US
• Employees: 174
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 27,154,530
• 10 Day Avg. Volume: 934,920
• 30 Day Avg. Volume: 829,622
• PEG Ratio: -0.03
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 3.31
• P/FCF Ratio: -7.59
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: 1.45
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $31.29
• Price Target Upside: 430.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $7.50 ▲(27.12% Upside)

Arcturus Therapeutics' overall stock score is primarily impacted by its financial performance, which is characterized by declining revenues and persistent losses. Technical analysis indicates bearish momentum, and valuation metrics are unattractive due to negative earnings. While there are positive developments in clinical trials, financial challenges and regulatory delays weigh heavily on the stock's outlook.

Positive Factors

Clinical Trial Progress

The progress in ARCT032's clinical trials indicates potential for successful treatment of cystic fibrosis, enhancing the company's pipeline and future revenue prospects.

Partnerships and Collaborations

Strategic partnerships, like with Meiji Seika Pharma, expand market reach and provide financial stability through shared resources and revenues.

Cash Runway Extension

A cash runway extending into 2028 provides financial stability, allowing Arcturus to continue R&D and strategic initiatives without immediate financial pressure.

Negative Factors

Revenue Decline

Significant revenue decline impacts financial health, limiting resources for R&D and potentially affecting long-term growth and market competitiveness.

Indefinite Delay in Costave BLA Filing

The indefinite delay in the Costave BLA filing hinders U.S. market entry, affecting potential revenue streams and strategic market positioning.

Increased Net Loss

Rising net losses indicate financial strain, reducing operational flexibility and potentially hindering investment in growth and innovation.

Arcturus Therapeutics Business Overview & Revenue Model

Company Description

Arcturus Therapeutics is a biopharmaceutical company specializing in the development of innovative RNA medicines, particularly focusing on mRNA technology for the treatment of various diseases. The company operates primarily in the biotechnology sector and is engaged in the research and development of therapeutics targeting significant unmet medical needs, including infectious diseases and rare genetic disorders. Arcturus's core products include its proprietary lipid-mediated delivery system for mRNA and a pipeline of drug candidates for conditions such as COVID-19 and cystic fibrosis.

How the Company Makes Money

Arcturus Therapeutics generates revenue primarily through partnerships and collaborations with other pharmaceutical companies and research institutions, which may involve upfront payments, research funding, and milestone payments as drug candidates progress through clinical trials. Additionally, the company may earn royalties from sales of products developed through such collaborations. Significant partnerships with larger biopharmaceutical firms enhance its financial stability and provide resources necessary for advancing its mRNA technology and clinical programs. Furthermore, government grants and funding for research initiatives can also contribute to its income stream.

Arcturus Therapeutics Financial Statement Overview

Summary

Arcturus Therapeutics faces significant financial challenges, with declining revenues and persistent losses impacting profitability and cash flow. While the balance sheet remains relatively stable with low leverage, the negative cash flow trends and profitability issues pose risks to financial stability.

Income Statement

Arcturus Therapeutics has experienced a significant decline in revenue from 2022 to TTM, with a negative revenue growth rate. The gross profit margin is positive, but the net profit margin is negative due to substantial net losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses. The equity ratio is strong, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Arcturus Therapeutics has negative free cash flow and operating cash flow, indicating cash burn. The free cash flow growth rate is negative, showing deterioration in cash generation. The ratios of operating and free cash flow to net income are not favorable, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	92.04M	138.39M	157.75M	205.75M	12.36M	9.54M
Gross Profit	88.70M	138.39M	157.75M	205.75M	12.36M	-46.41M
EBITDA	-68.74M	-77.40M	-24.16M	13.70M	-201.66M	-70.64M
Net Income	-66.71M	-80.94M	-29.73M	9.35M	-203.67M	-72.15M
Balance Sheet
Total Assets	282.34M	344.07M	429.40M	450.39M	392.81M	476.46M
Cash, Cash Equivalents and Short-Term Investments	180.36M	237.03M	292.00M	391.88M	370.49M	462.89M
Total Debt	21.86M	28.55M	30.22M	94.75M	69.15M	20.75M
Total Liabilities	57.78M	103.09M	150.89M	180.07M	164.60M	79.90M
Stockholders Equity	224.56M	240.98M	278.51M	270.31M	228.21M	396.55M
Cash Flow
Free Cash Flow	-58.65M	-60.40M	-21.00M	24.27M	-138.45M	-44.60M
Operating Cash Flow	-58.33M	-59.75M	-18.10M	31.99M	-135.04M	-42.86M
Investing Cash Flow	-318.00K	-648.00K	-2.90M	-7.73M	-3.41M	-1.74M
Financing Cash Flow	1.83M	5.42M	-24.09M	-2.86M	48.02M	436.14M

Arcturus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARCT, the sentiment is Negative. The current price of 5.9 is below the 20-day moving average (MA) of 8.53, below the 50-day MA of 15.25, and below the 200-day MA of 14.13, indicating a bearish trend. The MACD of -2.59 indicates Negative momentum. The RSI at 23.10 is Positive, neither overbought nor oversold. The STOCH value of 1.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARCT.

Arcturus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	77 Outperform	$756.55M	7.11	220.06%	―	79.13%	2798.12%
CMPX	60 Neutral	$871.52M	―	-37.82%	―	-100.00%	-28.79%
ARVN	56 Neutral	$740.51M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OLMA	46 Neutral	$1.33B	―	-59.22%	―	―	17.23%
ARCT	45 Neutral	$242.49M	-4.02	-27.43%	―	-41.53%	-11.32%
ERAS	34 Underperform	$783.04M	―	-32.00%	―	―	45.66%

Arcturus Therapeutics Corporate Events

Arcturus Therapeutics Earnings Call: Progress Amid Challenges

Arcturus Therapeutics’ recent earnings call painted a picture of mixed sentiments, with notable advancements in clinical trials and strategic partnerships. However, these positives were overshadowed by significant financial challenges, including a decline in revenue and an increased net loss. The indefinite delay in the Costave BLA filing emerged as a major hurdle for the company’s commercial prospects in the US market.

Arcturus Therapeutics Reports Q3 2025 Financials and Pipeline Progress

Arcturus Therapeutics Holdings Inc., based in San Diego, is a commercial mRNA medicines and vaccines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, with a focus on innovative RNA-based treatments.

Arcturus Therapeutics Advances Cystic Fibrosis Study with ARCT-032

Study Overview: Arcturus Therapeutics is conducting a Phase 2 study titled ‘A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis.’ The study aims to assess the safety, tolerability, and efficacy of ARCT-032 in adults with cystic fibrosis (CF) who cannot use CFTR modulators due to intolerance, poor response, or lack of access. This study is significant as it targets a population with limited treatment options.

Arcturus Therapeutics Advances with ARCT-810 Study for OTC Deficiency

Study Overview: Arcturus Therapeutics is conducting a Phase 2a study titled ‘A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency.’ The study aims to assess the safety and pharmacodynamics of ARCT-810, a potential treatment for OTC deficiency, a rare genetic disorder. This research is significant as it could lead to new therapeutic options for managing this condition.

Arcturus Therapeutics Announces Phase 2 Trial Results

On October 22, 2025, Arcturus Therapeutics announced interim results from its Phase 2 clinical trial of ARCT-032, an investigational mRNA therapy for cystic fibrosis, marking a significant step in its therapeutic development. Additionally, the company is involved in a legal dispute with AbbVie Inc. and others over trade secrets, and is working with CSL Seqirus on regulatory processes for KOSTAIVE, a self-amplifying mRNA vaccine, facing new FDA requirements for additional data.

The most recent analyst rating on (ARCT) stock is a Buy with a $49.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.

Arcturus Therapeutics Partners on New COVID-19 Vaccine Launch

On September 26, 2025, Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., launched KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine in Japan. This vaccine targets the SARS-CoV-2 Omicron sublineage JN.1 variant XEC and has shown efficacy against multiple variants in non-clinical studies. The launch follows a distribution agreement with CSL Seqirus for sales in Japan, marking a significant step in the company’s efforts to combat COVID-19.

The most recent analyst rating on (ARCT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.

Arcturus Therapeutics’ Earnings Call Highlights Progress and Optimism

Arcturus Therapeutics’ recent earnings call conveyed a generally positive sentiment, highlighting significant progress in key therapeutic programs, financial stability, and advancements in regulatory processes. Despite a decrease in revenue, the company’s strategic restructuring and strong financial position, along with promising clinical trial results, contribute to an optimistic future outlook.

Arcturus Therapeutics’ COVID-19 Vaccine Approved in Japan

On August 29, 2025, Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., announced the approval in Japan for KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This vaccine targets the SARS-CoV-2 Omicron sub lineage JN.1 variant XEC and has shown efficacy against several other variants in non-clinical studies. The vaccine is supplied as a two-dose vial and distribution is set to begin in late September 2025. This development follows a distribution agreement with CSL Seqirus for the Japanese market, potentially strengthening the company’s position in the vaccine industry.

The most recent analyst rating on (ARCT) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.